Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Ongoing monitoring schedules typically include: HbA1c testing every 36 months until stable, then 6-monthly to assess glycaemic control and determine whether treatment targets are being achieved
Control Placebo/other active drugs/standard of care
This is the "secret sauce" of bioavailability
Key points Cardiovascular outcome trials in individuals with type 2 diabetes mellitus demonstrate that glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce the rates of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death
US$ 23.04
US$ 22.19
US$ 27.11
US$ 21.77
US$ 27.38
